进退维谷：心房颤动患者抗凝治疗相关出血后的卒中预防

doi:10.3969/j.issn.1673-5765.2021.08.001

摘要/Abstract

孙伟, 张玉生. 进退维谷：心房颤动患者抗凝治疗相关出血后的卒中预防[J]. 中国卒中杂志, 2021, 16(08): 757-761.

SUN Wei, ZHANG Yu-Sheng. Dilemma in Anticoagulation Field: Stroke Prevention after Anticoagulation-Related Hemorrhage in Patients with Atrial Fibrillation[J]. Chinese Journal of Stroke, 2021, 16(08): 757-761.

参考文献

[1] 王拥军，李子孝，谷鸿秋，等. 中国卒中报告2019（中
文版）（1）[J]. 中国卒中杂志，2020，15（10）：1037-
1043.
[2] 《中国脑卒中防治报告2019》编写组. 《中国脑卒中
防治报告2019》概要[J]. 中国脑血管病杂志，2020，
17（5）：272-281.
[3] ZHANG J，YANG X A，ZHANG Y，et al. Oral
anticoagulant use in atrial fibrillation-associated
ischemic stroke：a retrospective，multicenter survey
in northwestern China[J]. J Stroke Cerebrovasc Dis，
2017，26（1）：125-131.
[4] LI Y G，LIP G Y H. Stroke prevention in atrial
fibrillation：state of the art[J/OL]. Int J Cardiol，2019，
287：201-209[2021-05-25]. https：//doi.org/10.1016/j.
ijcard.2018.09.057.
[5] KURAMATSU J B，HUTTNER H B. Management
of oral anticoagulation after intracerebral
hemorrhage[J]. Int J Stroke Int J Stroke，2019，14（3）：

238-246.

[6] HAGERTY T，RICH M W. Fall risk and
anticoagulation for atrial fibrillation in the elderly：a
delicate balance[J]. Cleve Clin J Med，2017，84（1）：
35-40.
[7] JANUARY C T，WANN L S，CALKINS H，et al.
2019 AHA/ACC/HRS focused update of the 2014
AHA/ACC/HRS guideline for the management
of patients with atrial fibrillation：a report of the
american college of cardiology/american heart
association task force on clinical practice guidelines
and the heart rhythm society[J]. J Am Coll Cardiol，
2019，74（1）：104-132.
[8] STEFFEL J，VERHAMME P，POTPARA T S，et
al. The 2018 European Heart Rhythm Association
practical guide on the use of non-vitamin K
antagonist oral anticoagulants in patients with atrial
fibrillation[J]. Eur Heart J，2018，39（16）：1330-
1393.
[9] KIRCHHOF P，BENUSSI S，KOTECHA D，et al.
2016 ESC guidelines for the management of atrial
fibrillation developed in collaboration with eacts[J].
Europace，2016，18（11）：1609-1678.
[10] CHANG T Y，LIAO J N，CHAO T F，et al. Oral
anticoagulant use for stroke prevention in atrial
fibrillation patients with difficult scenarios[J/OL]. Int
J Cardiol Heart Vasc，2018，20：56-62[2021-05-25].
https：//doi.org/10.1016/j.ijcha.2018.08.003.
[11] LOPES R D，GUIMARAES P O，KOLLS B J，et
al. Intracranial hemorrhage in patients with atrial
fibrillation receiving anticoagulation therapy[J].
Blood，2017，129（22）：2980-2987.
[12] TSAI C T，LIAO J N，CHIANG C E，et al.
Association of ischemic stroke，major bleeding，
and other adverse events with warfarin use vs nonvitamin
K antagonist oral anticoagulant use in
patients with atrial fibrillation with a history of
intracranial hemorrhage[J/OL]. JAMA Network
Open，2020，3（6）：e206424[2021-05-25].
https：//doi.org/10.1001/jamanetworkopen.2020.6424.
[13] PISTERS R，LANE D A，NIEUWLAAT R，et al.
A novel user-friendly score（HAS-BLED）to assess
1-year risk of major bleeding in patients with atrial
fibrillation：the euro heart survey[J]. Chest，2010，
138（5）：1093-1100.
[14] LIP G Y，FRISON L，HALPERIN J L，et al.
Comparative validation of a novel risk score
for predicting bleeding risk in anticoagulated
patients with atrial fibrillation：the HAS-BLED
（hypertension，abnormal renal/liver function，stroke，
bleeding history or predisposition，labile inr，elderly，
drugs/alcohol concomitantly）score[J]. J Am Coll
Cardiol，2011，57（2）：173-180.
[15] 黄从新，张澍，黄德嘉，等. 心房颤动：目前的认识和
治疗建议（2018）[J]. 中华心律失常学杂志，2018，22
（4）：279-346.
[16] O'BRIEN E C，SIMON D N，THOMAS L E，et al.
The orbit bleeding score：a simple bedside score to
assess bleeding risk in atrial fibrillation[J]. Eur Heart
J，2015，36（46）：3258-3264.
[17] HIJAZI Z，OLDGREN J，LINDBACK J，et al.
The novel biomarker-based ABC（age，biomarkers，
clinical history）-bleeding risk score for patients
with atrial fibrillation：a derivation and validation
study[J]. Lancet，2016，387（10035）：2302-2311.
[18] FANG M C，GO A S，CHANG Y C，et al. A
new risk scheme to predict warfarin-associated
hemorrhage the atria（anticoagulation and risk
factors in atrial fibrillation）study[J]. J Am Coll
Cardiol，2011，58（4）：395-401.
[19] BERG D D，RUFF C T，MORROW D A. Biomarkers
for risk assessment in atrial fibrillation[J]. Clin Chem，
2021，67（1）：87-95.
[20] WALLENTIN L，HIJAZI Z，ANDERSSON
U，et al. Growth differentiation factor 15，a
marker of oxidative stress and inflammation，for
risk assessment in patients with atrial fibrillation：
insights from the apixaban for reduction in stroke
and other thromboembolic events in atrial fibrillation
（aristotle）trial[J]. Circulation，2014，130（21）：
1847-1858.
[21] HAGSTROM E，JAMES S K，BERTILSSON M，et
al. Growth differentiation factor-15 level predicts
major bleeding and cardiovascular events in patients
with acute coronary syndromes：results from the
plato study[J]. Eur Heart J，2016，37（16）：1325-
1333.
[22] BERG D D，RUFF C T，JAROLIM P，et al.
Performance of the abc scores for assessing the
risk of stroke or systemic embolism and bleeding
in patients with atrial fibrillation in engage af-timi
48[J]. Circulation，2019，139（6）：760-771.
[23] MATHEWS L，ISHIGAMI J，DING N，et
al. Cardiac biomarkers and subsequent risk of
hospitalization with bleeding in the community：
atherosclerosis risk in communities study[J/OL]. J
Am Heart Assoc，2020，9（5）：e013560[2021-05-
25]. https：//doi.org/10.1161/jaha.119.013560.
[24] MARTI-FABREGAS J，MEDRANO-MARTORELL
S，MERINO E，et al. MRI predicts intracranial
hemorrhage in patients who receive long-term oral
anticoagulation[J/OL]. Neurology，2019，92（21）：
e2432-e2443[2021-05-25]. https：//doi.org/10.1212/
wnl.0000000000007532.
[25] SOO Y，ABRIGO J M，LEUNG K T，et al. Risk
of intracerebral haemorrhage in chinese patients
with atrial fibrillation on warfarin with cerebral
microbleeds：the ipaac-warfarin study[J]. J Neurol
Neurosurg Psychiatry，2019，90（4）：428-435.
[26] WILSON D，AMBLER G，SHAKESHAFT C，et al.
Cerebral microbleeds and intracranial haemorrhage
risk in patients anticoagulated for atrial fibrillation
after acute ischaemic stroke or transient ischaemic
attack（CROMIS-2）：a multicentre observational
cohort study[J]. Lancet Neurol，2018，17（6）：539-
547.
[27] BADI M K，VILANILAM G K，GUPTA V，et al.
Pharmacotherapy for patients with atrial fibrillation
and cerebral microbleeds[J]. J Stroke Cerebrovas Dis，
2019，28（8）：2159-2167.
[28] STANTON R J，ECKMAN M H，WOO D，et
al. Ischemic stroke and bleeding clinical benefit
of anticoagulation in atrial fibrillation after
intracerebral hemorrhage[J]. Stroke，2020，51（3）：
808-814.
[29] DU H W，WILSON D，AMBLER G，et al. Small
vessel disease and ischemic stroke risk during
anticoagulation for atrial fibrillation after cerebral
ischemia[J]. Stroke，2021，52（1）：91-99.
[30] GOTO S，GOTO S，PIEPER K S，et al. New
artificial intelligence prediction model using serial
prothrombin time international normalized ratio
measurements in atrial fibrillation patients on
vitamin K antagonists：GARFIELD-AF[J]. Eur
Heart J Cardiovasc Pharmacother，2020，6（5）：301-
308.
[31] DOMEK M，GUMPRECHT J，MAZUREK M，et al.
Should we judge stroke risk by static or dynamic risk
scores? A focus on the dynamic nature of stroke and
bleeding risks in patients with atrial fibrillation[J]. J
Cardiovasc Pharmacol，2019，74（6）：491-498.
[32] BIFFI A，URDAY S，KUBISZEWSKI P，et
al. Combining imaging and genetics to predict
recurrence of anticoagulation-associated
intracerebral hemorrhage[J]. Stroke，2020，51（7）：
2153-2160.
[33] POGGESI A，BARBATO C，GALMOZZI F，et
al. Role of biological markers for cerebral bleeding
risk stratification in patients with atrial fibrillation
on oral anticoagulants for primary or secondary
prevention of ischemic stroke（STRAT-AF study）：
study design and methodology[J]. Medicina，2019，
55（10）：626.
[34] KURAMATSU J B，GERNER S T，SCHELLINGER
P D，et al. Anticoagulant reversal，blood pressure
levels，and anticoagulant resumption in patients with
anticoagulation-related intracerebral hemorrhage[J].
JAMA，2015，313（8）：824-836.
[35] CHAO T F，LIU C J，LIAO J N，et al. Use of oral
anticoagulants for stroke prevention in patients with
atrial fibrillation who have a history of intracranial
hemorrhage[J]. Circulation，2016，133（16）：1540-
1547.
[36] NEWMAN T V，CHEN N M，HE M Q，et
al. Effectiveness and safety of restarting oral
anticoagulation in patients with atrial fibrillation
after an intracranial hemorrhage：analysis of
medicare part d claims data from 2010-2016[J]. Am J
Cardiovasc Drugs，2020，20（5）：471-479.
[37] PROIETTI M，ROMITI G F，ROMANAZZI I，et
al. Restarting oral anticoagulant therapy after
major bleeding in atrial fibrillation：a systematic
review and meta-analysis[J/OL]. Int J Cardiol，2018，
261：84-91[2021-05-25]. https：//doi.org/10.1016/
j.ijcard.2018.03.053.
[38] PURRUCKER J C，HAAS K，WOLF M，et al.
Haernorrhagic transformation after ischaemic stroke
in patients taking non-vitamin k antagonist oral
anticoagulants[J]. J Stroke，2017，19（1）：67-76.
[39] KERNAN W N，OVBIAGELE B，BLACK H R，et
al. Guidelines for the prevention of stroke in patients
with stroke and transient ischemic attack：a guideline
for healthcare professionals from the American Heart
Association/American Stroke Association[J]. Stroke，
2014，45（7）：2160-2236.
[40] 中华医学会神经病学分会，中华医学会神经病学分
会脑血管病学组. 中国缺血性脑卒中和短暂性脑缺
血发作二级预防指南2014[J]. 中华神经科杂志，2015，
48（4）：258-273.
[41] SMYTHE M A，PARKER D，GARWOOD C L，
et al. Timing of initiation of oral anticoagulation
after acute ischemic stroke in patients with atrial
fibrillation[J]. Pharmacotherapy，2020，40（1）：55-
71.
[42] ROSE D Z，MERIWETHER J N，FRADLEY M G，
et al. Protocol for arest：apixaban for early prevention
of recurrent embolic stroke and hemorrhagic
transformation-a randomized controlled trial of
early anticoagulation after acute ischemic stroke in
atrial fibrillation[J/OL]. Frontiers in Neurology，2019，
10：975[2021-05-25]. https：//doi.org/10.3389/fneur.
2019.00975.